Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification of key patent grants in China and Canada. The Chinese patent office have granted Reapplix’s patent on the device used when producing a LeucoPatch, using the unique 3CP™ technology developed by the company (patent no. ZL201180045202.2). Furthermore, the Canadian patent office have also granted this patent (patent no. 2,811,777). Reapplix has strong patent protection across multiple key territories.